31R Stock Overview
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Revive Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.064 |
| 52 Week Low | CA$0.0054 |
| Beta | -0.22 |
| 1 Month Change | 0% |
| 3 Month Change | -20.63% |
| 1 Year Change | -75.25% |
| 3 Year Change | -96.88% |
| 5 Year Change | -88.89% |
| Change since IPO | -93.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 31R | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -28.6% | -4.3% | -0.9% |
| 1Y | -75.2% | -28.0% | 3.3% |
Return vs Industry: 31R underperformed the German Pharmaceuticals industry which returned -30.2% over the past year.
Return vs Market: 31R underperformed the German Market which returned 3.4% over the past year.
Price Volatility
| 31R volatility | |
|---|---|
| 31R Average Weekly Movement | 48.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 31R's share price has been volatile over the past 3 months.
Volatility Over Time: 31R's weekly volatility has decreased from 90% to 48% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Michael Frank | revivethera.com |
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation.
Revive Therapeutics Ltd. Fundamentals Summary
| 31R fundamental statistics | |
|---|---|
| Market cap | €8.55m |
| Earnings (TTM) | -€2.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs 31R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 31R income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$4.30m |
| Earnings | -CA$4.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.6% |
How did 31R perform over the long term?
See historical performance and comparison